– New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings – – Ongoing pivotal trial and FDA Type C meeting provide clear path ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results